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Stroke may be triggered by respiratory infections, including influenza. Influenza 
vaccination could therefore reduce risk of stroke. Previous studies of this association 
have shown conflicting results. We aimed to investigate whether influenza 
vaccination was associated with reduced risk of stroke.  
 
Methods 
We used a self-controlled case series design. The General Practice Research 
Database (GPRD) was used to extract records of patients aged 18 years or over 
recorded with stroke (fatal or non-fatal) from September 2001 to May 2009. 
Statistical modelling with conditional Poisson regression was employed to compute 
incidence rate ratios (IRR). The incidence rate of stroke in fixed time periods after 
influenza vaccination was compared with the incidence rate during a baseline period. 
 
Results 
There were 17,853 eligible individuals who received one or more influenza 
vaccinations and experienced a stroke during the observation period. The incidence 
of stroke was significantly reduced in the first 59 days following influenza vaccination 
compared with the baseline period. We found reductions of 55% (IRR 0.45; 95% CI 
0.36-0.57) in the first 1-3 days after vaccination, 36% (0.64; 0.53-0.76) at 4-7 days, 
30% (0.70; 0.61-0.79) at 8-14 days, 24% (0.76; 0.70-0.84) at 15-28 days and 17% 
(0.83; 0.77-0.89) at 29-59 days after vaccination. Early vaccination between 1 
September and 15 November showed a greater reduction in IRR compared to later 
vaccination given after mid-November. 
 
Conclusions  
Influenza vaccination is associated with a reduction in incidence of stroke. This study 
supports previous studies which have shown a beneficial association of influenza 
vaccination for stroke prevention.  
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Stroke is an important cause of mortality and morbidity, with health service costs 
even excluding social and economic costs in the UK estimated at around £2.8 billion 
per year.1 Non-modifiable risk factors for stroke such as age and family history, and 
modifiable factors including hypertension1 are present in only 50 to 60% of patients 
with ischaemic strokes, suggesting that there may be other triggers.2 
 
A systematic review of the potential triggers of ischaemic stroke found 12 studies 
citing infection including respiratory infection as a potential trigger, with a significant 
association between ischaemic stroke and infection within the previous week (OR = 
2.91; 95% CI, 1.41 to 6.00) or month (OR = 2.41; 95% CI, 1.78 to 3.27).3 Influenza 
has been particularly implicated,4, 5 where a tripling of the influenza rate was 
associated with about a 6% change in stroke occurrence rate.5 
 
This raises the possibility that treatment or prevention of influenza might also prevent 
stroke. Antibiotics have been shown to be ineffective in preventing stroke,6 and there 
are doubts about the effectiveness of antivirals for influenza.7 There is a possibility 
that influenza vaccination may be preventative for strokes. 
 
Influenza vaccination has been associated with a reduced risk of stroke in several 
observational studies,8-12 either alone or combined with pneumococcal vaccine.13 
Other studies have not confirmed this,14-16 and concern remains that bias and 
residual confounding may explain these conflicting findings.17 Key sources of bias 
include the healthy vaccinee effect, where those at lower risk from stroke are more 
likely to be vaccinated,18 and in contrast the effect of functional status,19 where 
people who are frailer are less likely to be vaccinated and more likely to suffer 
stroke.  
 
We previously carried out a nested case-control study to examine the association 
between influenza vaccination and stroke risk, and found a 24% reduction in the risk 
of stroke associated with influenza vaccination given within the same influenza 
season.20 Although we adjusted for  comorbidity and attempted to account for 
functional ability and frailty using general practice consultation and home visit rates, 
the results are still susceptible to residual confounding, particularly from the ‘healthy 
vaccinee’ effect, Due to this and the inconclusive evidence from other studies we 
aimed to further investigate the association between influenza vaccination and stroke 
using a self-controlled case series (SCCS) design, since this design implicitly 




We used a self-controlled case series (SCCS) design to investigate the association 
between stroke and influenza vaccination. The SCCS method compares incidence of 
stroke in cases only during different time periods following vaccination, with 
incidence during a baseline period. In this method, cases act as their own controls in 
the baseline period when they are not exposed to vaccination. By using cases only 
the SCCS method has the advantage of implicitly adjusting for all measured and 
unmeasured fixed confounding variables, and so can help to identify true causal 
effects.21, 22 The SCCS method therefore implicitly adjusts for unknown confounders 
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such as functional ability which are not routinely recorded in clinical records or 
databases provided that they do not vary with time during the observation period. We 
have used this method in a previous study investigating the association between 
influenza vaccination and acute myocardial infarction (AMI).23  
 
Data for the study were extracted from the General Practice Research Database 
(GPRD), now called the Clinical Practice Research Datalink (CPRD), a large 
computerised anonymised database representative of and comprising around 5% of 
the population of England and Wales.24 The GPRD includes demographic 
information, health behaviours, referrals and treatment outcomes, with good clinical 
information including stroke and deaths.25 Data are entered into clinical records by 
general practitioners (GPs) at the time of consultation, and recorded using Oxford 
Medical Information Systems (OXMIS) and Read codes. The study received 
independent UK National Health Service ethics approval.  
 
Study population and data sources 
The study cases were drawn from all quality assured (up-to-standard) practices 
included in the GPRD over a period of eight years. Cases included patients aged 18 
years or over recorded with stroke (fatal or non-fatal) registered with the GPRD 
practices from 1/09/2001 to 31/08/2009. Cases with a diagnosis of stroke prior to the 
start of the observation period were excluded from the study. 
 
We limited cases to those that had been registered with the same GP for five years 
preceding the date of diagnosis of stroke to ensure completeness of recording. 
Inclusion was also restricted to cases who had received an influenza vaccination at 
least once during the observation period and to those cases where stroke occurred 
after the first vaccination to ensure that all patients were eligible for influenza 
vaccination during the observation period.26 Cases not meeting these criteria were 
excluded.  
 
The incident or index date of stroke diagnosis was defined as the first date when the 
GP recorded a medical diagnosis code (as defined above) for fatal/non-fatal stroke 
on the patient’s clinical or referral record. Cases were excluded if the stroke incident 
date was identical to any of their influenza vaccination dates within the observation 
period because of the possibility that vaccination was given after the stroke occurred 
or that the stroke was recorded retrospectively on the influenza vaccination date 
(Figure 1).  
 
Sample size calculation  
Based on a two-sided 5% significance level and 90% power in order to detect an IRR 
of 0.9, a sample size of 6520 cases was required, assuming that 65% of the 
population were vaccinated and that 50% of the observation period would be an 
exposure risk period.27 
 
Statistical analyses 
Statistical modelling was done using conditional Poisson regression in Stata (version 
12) to compute the incidence rate ratios (IRR). The incidence rates of stroke in the 
risk periods after influenza vaccination were compared with the incidence rates 
during the baseline period. Influenza is typically seasonal and to take account of this 
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in the analysis calendar time was used as the underlying time line. The start of the 
observation period was taken from the date of the first influenza vaccination 
recorded after 1/09/2001. The end of the observation period was either 31/05/2009 
or the date of leaving the practice or death which ever occurred first. The baseline 
period was taken as the interval between 6 months (180 days) after vaccination or 
the following 30th April which ever occurred first up to 14 days before the next 
vaccination.  
 
Seasonality was included in the models by dividing the risk periods into one of four 
quarterly seasons: September to November; December to February; March to May 
and June to August. Age was grouped into ≤64 years and ≥65 years at baseline. We 
tested for interactions of influenza vaccination with age at the start of the observation 
period. Seasonally adjusted IRRs split by gender and vaccination timing were 
calculated. The vaccination timings were split into early (1 September to 15 
November) and late (16 November to 30 April) vaccinations. 
 
Cut-off points for exposure and baseline 
Cut-off points for risk periods and seasons were calculated and intervals between 
any two adjacent cut-off points determined for each year within the observation 
period. There were eight pre-defined risk periods including: the baseline period; 1-14 
days before vaccination and; 1-3 days; 4-7 days, 8-14 days; 15-28 days; 29-59 days; 
60-90 days; 91-120 days; 121-180 days post vaccination. The reason 1-14 days pre-
vaccination was considered as a separate interval was due to the fact that a stroke 
occurring during this period is likely to affect the subsequent likelihood of receiving 
an influenza vaccination. A reduced and statistically significant IRR during this period 
could indicate that vaccinations were less likely to be given in the first two weeks 
after a stroke.  
 
Results  
We identified 21981 first cases of stroke within the observation period; 4128 cases 
that either had not received any influenza vaccinations within the observation period 
or had a stroke diagnosis before their first vaccination date or on the same date as 
one of their vaccinations were excluded. For the final analysis therefore 17853 cases 
of stroke were included comprising 52.8% (9424) females and 47.2% (8429) males. 
The median age at first stroke diagnosis was 75 years (interquartile range 68-81 
years) and 85.7% (15303) were aged 65 and over. 
 
There was a significant reduction in the rate of stroke between 15 and 59 days 
following vaccination. Significant reductions in risk were also apparent in the 1-14 
days before and 1-14 days after vaccination (Table 1), possible reasons for which 
are discussed below. We found reductions of 55% (IRR 0.45; 95% CI 0.36-0.57) in 
the first 1-3 days after vaccination, 36% (0.64; 0.53-0.76) at 4-7 days, 30% (0.70; 
0.61-0.79) at 8-14 days, 24% (0.76; 0.70-0.84) at 15-28 days, and 17% (0.83, 0.77-
089) at 29-59 days after vaccination.  
 
The incidence rate ratios for influenza vaccination were similar in men and women 
There were reduced risks with early vaccination up to 59 days after vaccination, but 
no significant reductions for late vaccinations although numbers were small and so 
confidence intervals were wide (Table 2). 
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There was no significant interaction between age at the start of the observation 
period and the effect of influenza vaccination (p = 0.07, data not shown). We found 
no significant difference between patterns of risk in males and females (p = 0.25).  
 
Discussion  
Influenza vaccination was associated with a significant reduction in incidence of 
stroke in the first 59 days following vaccination. This protective effect of influenza 
vaccination, presumably due to prevention of stroke triggered by influenza, waned 
over four months following vaccination and was not statistically significant after 59 
days. 
 
An apparent reduction in risk 1-14 days before vaccination may have been due to 
patients being less likely to receive an influenza vaccination in the 14 days after 
stroke or possibly due to late entry of vaccination data. The reduction in risk in the 1-
3 days post-vaccination may be due to individuals being more likely to receive 
vaccination when they are feeling well, whereas individuals with prodromal 
symptoms of stroke or at immediate high risk of stroke may have been less likely to 
attend the GP for influenza vaccination because they were either hospitalised or too 
unwell for vaccine administration. The same may be true for the period 4-7 days after 
vaccination but the vaccine could be conferring immunity by this time also.28 The 
reduction in stroke incidence at 8-59 days is more likely to be due to a true effect of 
influenza vaccine reducing the risk of influenza-induced stroke.  
 
Strengths and limitations 
We used a large, representative and robust research database with sufficient power 
to detect effects with precision. We minimized selection bias by including all cases of 
stroke within the selected time period.29 We recognise that restricting our sample to 
patients who had been at the same general practice for five years could exclude 
certain groups, for example transient populations, those with a less settled lifestyle or 
older people who had moved into a care home, but it did ensure completeness of 
vaccination information. 
 
The SCCS design is more robust than other observational designs in comparing 
differences in outcomes within an individual over time, thus adjusting for unknown or 
unmeasured confounders that do not change over time while measuring differences 
that occur between people. It is therefore better at accounting for ‘healthy vaccinee’ 
effects and functional status, unlike other observational designs.22 Since the SCCS 
method only accounts for known and unknown confounders do not change over 
time, a caveat of the study design is that it does not account for within-person 
confounding due to confounders varying over the observational period. If an 
individual’s cardiovascular risk factors increase over the observation period then the 
likelihood of receiving the vaccine will also increase.23 To counter this effect we 
restricted our observational period in the analysis to include only time after the first 
recorded vaccination: any time prior to the first vaccination was excluded from the 
observation period.  
 
Within-person study designs may have lower precision and greater susceptibility to 
bias when long-term exposures are analysed particularly from changing exposure 
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probability.30 Our study design contained a period of fairly constant influenza risk and 
we assumed the influenza vaccination was protective over the entire influenza 
season albeit with waning efficacy.  
 
Comparison with existing literature 
A beneficial effect of influenza vaccination for preventing stroke8-11 has been found in 
previous observational studies20 in contrast with studies showing no effect of 
vaccination14, 15 or suggesting that the association is due to bias.17 Our findings are 
also in line with previous studies showing an association between influenza 
vaccination and reduction in risk of AMI, particularly for early influenza vaccination,23, 
31 but no reduction in risk with pneumococcal vaccination.31  
 
An early effect of vaccination is plausible because 59% of influenza vaccine 
recipients have protective antibody titres within one week of vaccination. The 
antibody response against influenza lasts four to six months.32 
 
A previous self-controlled case series study of risk of vascular events following 
respiratory infection or influenza vaccination, conducted by Smeeth and colleagues 
using a similar study design and data source,10 showed a risk reduction associated 
with a period up to 28 days following vaccination. Compared with this study, they 
used shorter risk periods and included an exposure period which extended up to 91 
days after vaccination with the remaining observation time included in the baseline 
period. Our study showed significant benefits up to 59 days following vaccination. 
This difference may reflect the choice of the baseline period where an assumption of 
constant risk needs to be postulated and the differences in post-vaccination risk 
periods selected. We assumed that the vaccine could offer protection over the entire 
influenza season.28, 32 The baseline period in our study therefore included a period of 
fairly constant influenza risk compared with Smeeth et al who used a baseline period 
with more variable influenza risk.23 
 
The mechanism by which influenza might precipitate stroke is not known but has 
been postulated to be due to various factors including non-specific immune 
stimulation,33 fever leading to endothelial dysfunction, hypercoagulability or 
increased viscosity, and stress or metabolic changes in response to infection. 
Influenza may cause atheroma,34 affect carotid plaque stability or promote rupture.35  
 
Implications for future research  
Our findings support current recommendations for influenza vaccination in people at 
high risk,36 but with the added effect of stroke prevention. If shown to be a causal 
effect, this may help improve suboptimal vaccination rates, particularly in at-risk 
groups.37 Early influenza vaccination was associated with greater reduction in stroke 
risk compared with later vaccination which should encourage early vaccination. 
 
The uncertainty about whether to extend vaccination to younger adults at risk of 
stroke, suggests that experimental studies are needed to confirm these findings, and 
before recommending changes in indications or timing of vaccination. 
 
If a causative link between influenza vaccination and reduction in stroke risk is 
confirmed by experimental studies and leads to higher vaccinations rates there 
would be significant benefits for patient and population health. 
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Figure 1 Study design: exposure and baseline period 
 
  
Observation period starts at vaccination date1
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Table 1 Association between influenza vaccination and stroke 
 
Risk period Number of cases Time at risk (person years) 
  
Adjusteda  
  N %    IRRb 95% CI  
            
Baseline periodc 10001 56.0 53738 1∙00 - 
Pre vaccination interval          
1-14 days 334 1.9 2983 0.55 0.49 - 0.61 
Post vaccination intervals         
1-3 days 72 0.4 733 0.45 0.36  - 0.57 
4-7 days 134 0.8 978 0.64 0.53  - 0.76 
8-14 days 256 1.4 1710 0.70 0.61  - 0.79 
15-28 days 552 3.1 3417 0.76 0.70 - 0.84 
29-59 days 1268 7.1 7545 0.83 0.77 - 0.89 
60-90 days 1388 7.8 7506 0.95 0.88 - 1.03 
91-120 days 1363 7.6 7212 0.99 0.92 - 1.06 
121-180 days 2485 13.9 13266 1.02 0.97 - 1.08 
            
a Adjusted for seasonality 
b IRR incidence rate ratio. 
c Baseline period is between 180 days or 30th of April (whichever came first) after vaccination and 14 




Table 2 Seasonally adjusted IRR by gender and vaccination timing for stroke 
 
 
 Risk period 
(days)  Gender Vaccination timing 
 Female Male Early (1 September to 15 November) 
Late (16 November to 30 
April) 
  Cases Adjusted Cases Adjusted Cases Adjusted Cases Adjusted 
  N IRRa 95% CI N IRR 95% CI N IRR 95% CI N IRR 95% CI 
Baseline period 5349 1 - 4652 1 - 10097 1 - 17757 1 - 
                          
Pre vaccination interval                       
1-14 days 170 0.54 0.46 - 0.64 164 0.65 0.47 - 0.65 330 0.55 0.49 - 0.61 4 0.49 0.18 - 1.31 
Post vaccination intervals                   
1-3 days 35 0.42 0.30 - 0.59 37 0.48 0.35 - 0.67 70 0.45 0.35 - 0.57 2 0.78 0.19 - 3.15 
4-7 days 56 0.51 0.39 - 0.66 78 0.78 0.62 - 0.98 132 0.64 0.53 - 0.76 2 0.59 0.15 - 2.37 
8-14 days 138 0.72 0.60 - 0.86 118 0.68 0.56 - 0.82 251 0.70 0.61 - 0.79 5 0.84 0.35 - 2.04 
15-28 days 298 0.79 0.70 - 0.89 254 0.74 0.64 - 0.84 538 0.76 0.69 - 0.83 14 1.18 0.69 - 2.03 
29-59 days 639 0.78 0.71 - 0.86 629 0.88 0.80 - 0.97 1240 0.83 0.77 - 0.88 28 1.13 0.77 - 1.66 
60-90 days 757 0.95 0.86 - 1.05 631 0.96 0.86 - 1.07 1363 0.96 0.89 - 1.03 25 1.10 0.73 - 1.64 
91-120 days 693 0.93 0.84 - 1.03 670 1.07 0.96 - 1.18 1351 1.00 0.93 - 1.08 12 0.68 0.38 - 1.21 
121-180 days 1289 1.01 0.94 - 1.09 1196 1.04 0.97 - 1.13 2481 1.03 0.97 - 1.08 4 0.83 0.31 - 2.21 
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